The EMA's CHMP committee recommendation is for Alofisel (darvadstrocel) to treat the serious complication, which the Tigenix and Takeda say affects around 28% of patients with Crohn's disease in ...
Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback